Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pulmonary/Respiratory Diseases
Disease Category: Idiopathic Pulmonary Fibrosis
Trial Information
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
[PIPF-004]
The purpose of this study is to measure the safety and effectiveness of two different doses (2403mg and 1197 mg) of pirfenidone as compared to placebo in patients with (Idiopathic Pulmonary Fibrosis) IPF. Placebo is a capsule that looks identical to pirfenidone but contains no active medicine. Participation will include 13 visits to the clinic over a 60 week period (about 1 year). All study medications and procedures will be provided at no cost.
No Compensation Provided
Patient Inclusion/Exclusion Criteria:
You may be eligible to participate if you:
-are a male or female between 40 to 80 years old
-have symptoms of Idiopathic Pulmonary Fibrosis
-meet additional criteria
You will not be able to participate if you:
-have ever used pirfenidone
-have a history of drug or alcohol abuse in the past 2 years
-are pregnant or breastfeeding
Adriana Rodriguez, Clinical Research Coordinator
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 212-241-5137
Fax: 212-831-3560
EMail: adriana.rodriguez@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
